ALKERMES | ALKS - Equity Capital And Reserves


ALKERMES reported $1.86B in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -4.58B 1.35B Sep/2026
Acadia Pharmaceuticals USD 1.39B 80.88M Sep/2026
ALKERMES USD 1.86B 56.17M Sep/2026
Amgen USD 14.35B 2.66B Sep/2026
Biogen USD 19.04B 194.3M Sep/2026
BioMarin Pharmaceutical USD 6.26B 65.66M Sep/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Coherus Biosciences USD 60.84M 17.78M Jun/2026
Eli Lilly USD 40.27B 6.39B Sep/2026
Gilead Sciences USD 13.04B 1.3B Sep/2026
Heron Therapeutics USD 4.92M 1.99M Sep/2026
Ionis Pharmaceuticals USD 393.64M 46.1M Sep/2026
J&J USD 81.53B 3.44B Sep/2026
Malin Corporation EUR 193.2M 75M Dec/2024
Merck USD 44.89B 2.96B Sep/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.88B 185.1M Sep/2026
Otsuka Holdings JPY 3.29T 45.95B Sep/2026
Ovoca Bio EUR 780K 485K Dec/2025
Pfizer USD 89B 3.81B Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Vertex Pharmaceuticals USD 20.91B 659.5M Sep/2026